Health Care [ 3/12 ] | Pharmaceuticals [ 37/74 ]
NYSE | Common Stock
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
The company operates through three segments: Generics, Specialty, and AvKARE.
The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.
The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders.
This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease.
The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs.
This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers.
It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies.
The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018.
Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 8, 24 | 0.16 Decreased by -15.79% | 0.13 Increased by +23.08% |
| Aug 9, 24 | 0.16 Decreased by -15.79% | 0.14 Increased by +14.29% |
| May 3, 24 | 0.14 Increased by +16.67% | 0.09 Increased by +55.56% |
| Mar 1, 24 | 0.14 Decreased by -39.13% | 0.09 Increased by +55.56% |
| Nov 7, 23 | 0.19 Increased by +35.71% | 0.13 Increased by +46.15% |
| Aug 4, 23 | 0.19 Increased by 0.00% | 0.11 Increased by +72.73% |
| May 5, 23 | 0.12 Increased by 0.00% | 0.10 Increased by +20.00% |
| Mar 2, 23 | 0.23 Increased by +27.78% | 0.21 Increased by +9.52% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 702.47 M Increased by +13.29% | -156.00 K Decreased by -101.61% | Decreased by -0.02% Decreased by -101.42% |
| Jun 30, 24 | 701.78 M Increased by +17.15% | 5.99 M Decreased by -49.70% | Increased by +0.85% Decreased by -57.07% |
| Mar 31, 24 | 659.19 M Increased by +18.23% | -91.64 M Decreased by -807.90% | Decreased by -13.90% Decreased by -667.89% |
| Dec 31, 23 | 616.98 M Increased by +1.18% | -98.65 M Decreased by -1.58 K% | Decreased by -15.99% Decreased by -1.56 K% |
| Sep 30, 23 | 620.04 M Increased by +13.65% | 9.68 M Increased by +505.10% | Increased by +1.56% Increased by +456.44% |
| Jun 30, 23 | 599.05 M Increased by +7.10% | 11.92 M Increased by +104.96% | Increased by +1.99% Increased by +104.63% |
| Mar 31, 23 | 557.54 M Increased by +12.04% | -10.09 M Decreased by -56.25% | Decreased by -1.81% Decreased by -39.46% |
| Dec 31, 22 | 609.76 M Increased by +13.57% | -5.86 M Increased by +8.14% | Decreased by -0.96% Increased by +19.12% |